Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Open-label, Phase II Trial, to Evaluate the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Patients With HER2-negative Breast Cancer (The Phenomenal Study)

NCT03328884 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT03328884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03328884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Open-label, Phase II Trial, to Evaluate the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Patients With HER2-negative Breast Cancer (The Phenomenal Study)
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Completed
Start date
May 2, 2017
Completion date
April 2, 2025
Enrollment
55 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer metastatic